



# Neurofilaments in progressive multiple sclerosis: a systematic review

Thomas Williams<sup>1</sup> · Henrik Zetterberg<sup>2,3,4,5</sup> · Jeremy Chataway<sup>1,6</sup>

Received: 26 March 2020 / Revised: 11 May 2020 / Accepted: 13 May 2020 / Published online: 23 May 2020  
© The Author(s) 2020

## Abstract

**Background** Neurofilament proteins have been extensively studied in relapsing–remitting multiple sclerosis, where they are promising biomarkers of disease activity and treatment response. Their role in progressive multiple sclerosis, where there is a particularly urgent need for improved biomarkers, is less clear. The objectives of this systematic review are to summarise the literature on neurofilament light and heavy in progressive multiple sclerosis, addressing key questions.

**Methods** A systematic search of PubMed, Embase, Web of Science and Scopus identified 355 potential sources. 76 relevant sources were qualitatively reviewed using QUADAS-2 criteria, and 17 were identified as at low risk of bias. We summarise the findings from all relevant sources, and separately from the 17 high-quality studies.

**Results** Differences in neurofilament light between relapsing–remitting and progressive multiple sclerosis appear to be explained by differences in covariates. Neurofilament light is consistently associated with current inflammatory activity and future brain atrophy in progressive multiple sclerosis, and is consistently shown to be a marker of treatment response with immunosuppressive disease-modifying therapies. Associations with current or future disability are inconsistent, and there is no evidence of NFL being a responsive marker of purportedly neuroprotective treatments. Evidence on neurofilament heavy is more limited and inconsistent.

**Conclusions** Neurofilament light has shown consistent utility as a biomarker of neuroinflammation, future brain atrophy and immunosuppressive treatment response at a *group* level. Neither neurofilament light or heavy has shown a consistent treatment response to neuroprotective disease-modifying therapies, which will require further data from successful randomised controlled trials.

**Keywords** Progressive multiple sclerosis · Multiple sclerosis · Biomarkers · Neurofilament light chain (NFL) · Neurofilament heavy chain (NFH)

---

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s00415-020-09917-x>) contains supplementary material, which is available to authorized users.

✉ Thomas Williams  
Thomas.williams@nhs.net

<sup>1</sup> Department of Neuroinflammation, Faculty of Brain Sciences, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, University College London, London, UK

<sup>2</sup> Department of Neurodegenerative Disease, Faculty of Brain Sciences, UCL Queen Square Institute of Neurology, University College London, London, UK

## Introduction

Progressive multiple sclerosis (PMS) is characterised by a steady accumulation of disability largely independent of relapses [1]. In primary progressive multiple sclerosis (PPMS), progression occurs from onset without preceding relapses; in secondary progressive multiple sclerosis (SPMS), progression follows an initial relapsing and

<sup>3</sup> UK Dementia Research Institute, University College London, London, UK

<sup>4</sup> Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy At the University of Gothenburg, Mölndal, Sweden

<sup>5</sup> Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

<sup>6</sup> Biomedical Research Centre, National Institute for Health Research, University College London Hospitals, London, UK

remitting phase of the disease. In both cases, progression may occur either in association with inflammatory activity (active progression), or in the absence of such inflammatory activity (non-active progression) [1].

In contrast to relapsing–remitting multiple sclerosis (RRMS), where there has been a rapid expansion in available treatments, few treatments are available for PMS, and these are restricted to those with active progression. There is a clear need to innovate the therapeutic pipeline, particularly in non-active PMS, to enhance the development of novel treatments. This ideally would involve moving beyond MRI-based biomarkers of treatment efficacy in clinical trials. A lead candidate for this is neurofilament light (NFL), and to a lesser extent neurofilament heavy (NFH), cytoskeletal proteins released from neurones following injury. With the advent of highly sensitive digital enzyme-linked immunoassay (ELISA), also called Single molecule array (Simoa), platforms, neurofilaments can now be sensitively quantified in both cerebrospinal fluid (CSF) and blood, making application to large cohorts and clinical trials a practical reality [2].

In RRMS, neurofilaments are associated with clinical and MRI inflammatory activity, and predict future disability progression [3–5]. Their ability to demonstrate treatment response has led to the suggestion that NFL may replace established MRI-based outcomes in phase 2 trials in RRMS [6]. Similarly, if issues around assay standardisation and inter-laboratory precision can be resolved, and larger datasets on normative values established, serial bNFL monitoring is likely to become part of standardised disease activity monitoring in RRMS in the near future [7, 8]. RRMS studies will not be considered further in this review.

The place of neurofilaments in PMS, however, is less well studied, and the underlying association with inflammatory activity questions their utility in non-active PMS.

The aims of this systematic review are to qualitatively summarise the literature on the role of neurofilaments (NFL and NFH, CSF and blood) in PMS. Specific questions include:

1. In patients with PMS, are neurofilament concentrations in CSF or blood associated with current disease course and cross-sectional measures of inflammatory activity and disability?
2. In patients with PMS, are neurofilament concentrations in CSF or blood associated with future measures of disability progression?
3. In patients with PMS, are neurofilament concentrations responsive markers of disease-modifying treatment (DMT) in observational or randomised controlled trials?

## Methods

Our systematic review was guided by PRISMA [9]. Any original study reporting neurofilament data in patients with PMS was identified. We included published research papers, conference abstracts and conference presentations, with no restrictions on date or language. In studies including mixed cohorts of patients (RRMS and PMS), data had to be separately presented or described for PMS to be included.

One author developed a searched strategy and interrogated PubMed, Embase, Web of Science and Scopus in December 2019 using the search terms (“neurofilament” OR “neurofilaments”) AND (“progressive” AND “multiple sclerosis”). We identified 463 records (Fig. 1), and a further ten records were identified from a review of online conference libraries and the author’s own records. 118 duplicates were removed and a further 239 records were removed following a review of abstracts. The most common reasons for record exclusion were that no original data were reported, records reported histological or animal data rather than human fluid biomarkers, or that no PMS patients were included in the study. The remaining 116 records were reviewed in full, and a further 40 excluded as they did not separately report neurofilament findings in PMS-only cohorts or contained datasets already included from other records.


The remaining 76 records were qualitatively reviewed. The QUADAS-2 tool was used to assess for risk of bias. For each publication, the reference standard was defined as that to which the neurofilament data was being compared. The PRISMA table and literature review data are available in Online Resources 1 and 2. Due to the limited number of high-quality studies, we first present a qualitative review of all eligible studies regardless of QUADAS scoring, to give the most complete review of the literature. We shall then summarise the 17 high-quality studies separately. Summary statistics were obtained from the published records. A quantitative meta-analysis was not undertaken due to heterogeneity in the data (CSF and blood, variability in assays used to quantify neurofilament), and limits on data availability from conference abstracts and presentations.

## Results

### Neurofilament light

#### NFL—associations with disease course

A number of studies (including 312 PMS patients) have reported that CSF or blood NFL (cNFL/bNFL) is *higher* in PMS compared to RRMS [4, 5, 10–19], or that it increases more quickly in PMS [20]. Others, however, report that NFL



**Fig. 1** PRISMA Flow Diagram. Due to the limited number of studies at low risk of bias, all literature applicable to each review question is first summarised, followed by a summary of studies at low risk of

bias. A quantitative meta-analysis was not undertaken due to heterogeneity in study data and limited data availability

is *lower* in PMS compared to RRMS [21–23] or controls [24]. The majority of studies found no significant difference between disease stages [25–38].

Concurrent disease activity significantly impacts comparisons of NFL between disease states. RRMS in remission have similar cNFL to PMS [25, 39, 40], a finding replicated in a recent meta-analysis—a significant difference between

RRMS and PMS patients was lost once patients currently experiencing a relapse were excluded [41].

Similarly, two studies have reported associations between bNFL and disease course in univariate analyses, but this significance is lost in multivariate analyses, where significance only persisted for age, EDSS, recent relapses and DMT treatment status [4, 5]. One large study has reported comparisons between bNFL in PMS subtypes, suggesting that bNFL is

higher in SPMS compared to PPMS. This persists independent of MRI inflammatory activity [42].

### NFL and disease activity in PMS

Disease activity was defined as either recent relapses, T1 GAD-enhancing lesions or new/enlarging T2 lesions. Replicating findings in RRMS populations, both cNFL and bNFL have been consistently reported to be higher in PMS patients with disease activity compared to PMS patients without disease activity [3, 41–48]. A minority of studies reported no such associations between c/bNFL and disease activity in PMS [5, 49, 50].

### NFL and current disability

Measuring disability through EDSS, timed 25-foot walk or nine-hole peg test, both cNFL and bNFL have been associated with current disability in PMS [4, 10, 12, 19, 37, 42, 47]. cNFL has also been associated with cognitive performance [51]. There is, however, heterogeneity in the literature, with a number of studies reporting no such association with cNFL [35, 43, 44, 52–58] or bNFL [58, 59].

### NFL and cross-sectional MRI biomarkers

Beyond measures of disease activity, NFL has been associated with other MRI biomarkers of MS pathology. cNFL has been reported to be associated with cortical thickness, T1 hypointense lesion volume and magnetisation transfer ratios in normal appearing white matter and grey matter [49, 57, 60]. In larger studies of sNFL, associations have been found with T2 lesion volume [42, 46, 47], and a recent study has found associations with the presence of chronic active lesions. The latter were defined by the presence of paramagnetic rims on T2\* sequences, and PMS patients with two or more chronic active lesions had significantly higher sNFL compared to those with 0–1 chronic active lesions [61].

### NFL and other biomarkers of inflammatory activity or disability

In addition to the associations with clinical and MRI evidence of disease activity, cNFL has been reported in association with other fluid biomarkers of CNS inflammatory activity, including osteopontin, CXCL13, CSF lymphocyte count, CSF IgG index, sCD27 and sCD14 [44, 60, 62]. Both cNFL and bNFL have also been associated with markers of glial pathology, including glial fibrillary acidic protein (GFAP), chitinase-3-like 1 protein (CHI3L1) and soluble triggering receptor expressed on myeloid cells 2 (sTREM2) [35, 37, 44, 45, 58, 62]. A single study found associations between bNFL and ocular coherence tomography (OCT) markers of

neurodegeneration, but this was not significant in the PMS-only cohort [63].

### NFL and future disability

Two studies have reported associations between baseline cNFL and future disability progression in PMS cohorts [54, 64], whilst another found no association [65]. With bNFL, one study reported no association with future disability progression [10], but this is contradicted by three larger studies. In the ORATORIO study of ocrelizumab in PPMS, a tenfold increase in baseline bNFL in the control group was associated with increased risk of progression on 9-hole peg test and 25-foot walk (HR 2.33 and 5.35,  $p=0.036$  and  $0.003$ , respectively) [28]. In the EXPAND and INFORMS studies of siponimod in SPMS, and fingolimod in PPMS, respectively, a baseline bNFL > 30 pg/ml was associated with significantly greater confirmed disability progression (HR 1.32,  $p=0.006$  in SPMS; HR 1.49,  $p=0.027$  in PPMS) [42].

### NFL and future MRI biomarkers of progression

Both baseline cNFL and bNFL have consistently been associated with future brain or spinal cord atrophy. In the EXPAND and INFORMS studies, baseline bNFL was grouped into low (< 30 pg/ml), medium (30–60 pg/ml) or high (> 60 pg/ml), and the high bNFL group experienced more than double the rate of brain atrophy at 24 months compared to low bNFL ( $p < 0.001$ , both studies) [42]. Similarly, in the ASCEND study of natalizumab in SPMS, higher baseline bNFL was associated with greater 96 week brain atrophy ( $p < 0.0001$ ) [47], a finding replicated with cNFL in a smaller cohort from the MS-SMART study (also SPMS,  $p=0.02$ ) [65]. In a mixed PMS observational cohort, patients whose baseline bNFL was above the 99th percentile of a control cohort experienced greater brain and spinal cord atrophy at 2- and 5-year follow-ups [5].

### NFL as a biomarker of treatment effect

Multiple studies have assessed cNFL as a biomarker of treatment effect in open-label studies in PMS. Significant reductions were demonstrated with natalizumab, rituximab or mitoxantrone, and in a mixed cohort starting various first- or second-line DMTs [3, 43, 60]. Case reports have reported similar findings with subcutaneous cladribine [66]. No treatment effect on cNFL was seen with monthly methylprednisolone, intrathecal mesenchymal stem cells, intrathecal and intravenous rituximab, intraventricular rituximab, dimethyl fumarate and intrathecal methotrexate [67–72].

**Table 1** Key findings for neurofilament light in progressive multiple sclerosis—all eligible studies

	Supports	Against
NFL is higher in PMS compared to RRMS—all	Nine Studies, <i>n</i> = 609 RRMS vs. 312 PMS	14 studies, <i>n</i> = 1811 RRMS vs. 912 PMS
Difference in NFL between RR and PMS are lost if recent activity is excluded/covariates controlled for	Six studies, <i>n</i> = 610 RRMS vs. 298 PMS	–
NFL is associated with inflammatory activity	Nine studies, <i>n</i> = 3171	Three studies, <i>n</i> = 148
NFL is associated with current disability—EDSS	Six studies, <i>n</i> = 2036	11 studies, <i>n</i> = 476
NFL is associated with current disability—MSFC	One study, <i>n</i> = 744	–
NFL is associated with future disability worsening—EDSS	Three studies, <i>n</i> = 1881	Two studies, <i>n</i> = 587
NFL is associated with future brain atrophy	Four studies, <i>n</i> = 1680	–
Licensed disease-modifying therapies for RRMS show a treatment effect upon NFL in PMS—open label	Four studies, <i>n</i> = 111	One study, <i>n</i> = 16
Immunosuppressive disease-modifying therapies show a treatment effect upon NFL in PMS—RCTs	Four studies, <i>n</i> = 3090	–
Purportedly neuroprotective disease-modifying therapies show a treatment effect upon NFL—open label or RCT	–	Two studies, <i>n</i> = 320 (60 open label, 255 RCT)

Inflammatory activity was defined as either recent relapses, T1 GAD-enhancing lesions or new/enlarging T2 lesions

NFL neurofilament light, RRMS relapsing–remitting multiple sclerosis, PMS progressive multiple sclerosis, EDSS expanded disability status scale, MSFC multiple sclerosis functional composite, RCT randomised controlled trial

In randomised, placebo controlled trials in PMS, a significant treatment effect upon bNFL has been shown with fingolimod, natalizumab, siponimod and ocrelizumab [28, 42, 47, 73]. With natalizumab, siponimod and ocrelizumab, the treatment effect is more marked in PMS with evidence of recent inflammatory activity at baseline (either relapses or GAD + lesions) compared to those without recent inflammatory activity. For natalizumab and siponimod, subgroups of patients without recent inflammatory activity still demonstrated a significant treatment response on bNFL [47, 73].

In contrast, a randomised, placebo controlled trial of ibudilast in PMS did not show a treatment effect upon bNFL, and in an open-label study of high-dose biotin [50], bNFL was not reduced following 2 years of treatment [48, 50].

Key results for NFL in PMS are summarised in Table 1.

## Neurofilament heavy

### NFH—associations with disease course

As for NFL, there is heterogeneity in reports comparing NFH in PMS and RR patients. Some studies have reported c/bNFH to be higher or increase more rapidly in PMS compared to RRMS or clinically isolated syndromes (CIS) [26, 74–78]; whilst others have found no difference [79–82].

### NFH and current disability

Measuring disability by EDSS, 25FW, 9HPT, MSSS or ambulatory index, both cNFH and bNFH have been associated with current disability in PMS [54, 65, 76, 78, 83]. Other studies have found no association with EDSS [54, 79]. bNFH has also been associated with cognitive performance on the Paced Auditory Serial Addition Test (PASAT) [83].

### NFH and MRI biomarkers

No data were found to support associations between NFH and MRI inflammatory activity. bNFH has, however, been associated with lower magnetisation transfer ratios and greater central cerebral volume loss, but not T2 lesion volume [83].

### NFH and future disability

One study of cNFH has shown associations with future disability; whilst another associated a high blood–CSF NFH ratio with disability progression [65, 84]. Others have reported no such association [54, 83]. One study reported an association between baseline cNFH and subsequent whole-brain atrophy over 2 years [65].

**Table 2** Key findings for neurofilament heavy in progressive multiple sclerosis—all eligible studies

Summary of key findings—NFH		
	Supports	Against
NFH is higher in PMS compared to RRMS—all	Three studies, 116 RRMS vs. 88 PMS	Four studies, 130 RRMS vs. 85 PMS
NFH is associated with current EDSS	Three studies, $n = 217$	Two studies, $n = 79$
NFH is associated with future disability	One study, $n = 70$	One study, $n = 31$

NFH neurofilament heavy, RRMS relapsing–remitting multiple sclerosis, PMS progressive multiple sclerosis, EDSS expanded disability status scale

### NFH as a biomarker of treatment effect

Few studies have reported analyses of treatment effects using NFH. One very short study reported no change in cNFH over 8 days following treatment with intrathecal triamcinolone [82]. In an open-label study of HSCT, bNFH was significantly increased 1 month after HSCT, remaining elevated for 1 year. The increase was greater than

that seen in haematology patients undergoing HSCT and untreated SPMS controls, suggesting possible vulnerability to chemotherapy-induced neurotoxicity in PMS [85]. In a randomised, placebo controlled trial of lamotrigine in SPMS, no treatment effect on bNFH was seen in the intention to treat population. Treatment compliance rates in this trial, however, were low, and on a secondary analysis of

**Table 3** Key findings from studies at low risk of bias on neurofilament light or neurofilament heavy in progressive multiple sclerosis

Study question	NFL or NFH	Studies	$n$	Reported results
Association with disease course	NFL	2	1757	bNFL is higher in SPMS compared to PPMS
		2	115	After controlling for significant covariates, bNFL not higher in PMS than RRMS
Association with current disability	NFL	4	1874	bNFL is associated with current EDSS
		6	1143	NFL is not associated with current EDSS (bNFL = 900, cNFL = 243)
		1	744	bNFL is associated with current 25FW and 9HPT
	NFH	2	190	NFH is associated with current or future EDSS (bNFH, $n = 120$ , cNFH, $n = 70$ )
Association with current inflammatory activity	NFL	1	48	cNFH is not associated with EDSS
		10	3533	NFL is associated with inflammatory activity. cNFL, $n = 176$ ; bNFL, $n = 3357$ )
Association with future disability worsening	NFL	2	133	bNFL is not associated with inflammatory activity
		2	1757	bNFL is associated with increased risk of EDSS progression
		3	1330	NFL is not associated with increased risk of EDSS progression (bNFL, $n = 1260$ ; cNFL, $n = 70$ )
Association with future brain atrophy	NFL	1	516	bNFL is associated with worsening 25FW and 9HPT
		5	2337	Baseline NFL is associated with future brain atrophy (bNFL, $n = 2267$ ; cNFL, $n = 70$ )
		1	68	Baseline bNFL is associated with future spinal atrophy
Treatment effect	NFL	1	70	Baseline cNFH is associated with future brain atrophy
		4	3020	bNFL is reduced by immunosuppressive disease-modifying treatment
	NFH	1	255	bNFL is not reduced by ibudilast
	NFH	1	120	bNFH is not reduced by lamotrigine in the ITT population, but is reduced in per-protocol compliant participants

Inflammatory activity was defined as either recent relapses, T1 GAD-enhancing lesions or new/enlarging T2 lesions

bNFL blood neurofilament light, cNFL CSF neurofilament light, bNFH blood neurofilament heavy, cNFH CSF neurofilament heavy, RRMS relapsing–remitting multiple sclerosis, PMS progressive multiple sclerosis, EDSS expanded disability status scale, 25FW timed 25-foot walk, 9HPT 9-hole peg test, ITT intention to treat ANALYSIS

treatment-compliant participants, bNFH was reduced in those taking lamotrigine [83].

Key findings for NFH in PMS are summarised in Table 2.

### Summary of studies at low risk of bias included following QUADAS-2 review

Following QUADAS-2 scoring, 17 studies on NFL and three on NFH were found to be at low risk of bias. These consisted of larger cohort studies and randomised controlled trials, and are summarised in Table 3.

The conclusions were broadly in line with those of all eligible studies. For NFL, the most consistent findings were found for associations with recent disease activity and future brain atrophy, and for the ability of immunosuppressive disease-modifying therapies to show a treatment effect upon blood NFL [3, 5, 28, 43–48, 50, 65, 73]. Associations between NFL and current or future disability were less consistent, and in the single positive phase 2 randomised controlled trial of a purportedly neuroprotective therapy, there was no treatment effect upon NFL [4, 10, 28, 35, 43, 44, 47, 48, 56, 58, 73]. Limited conclusions can be drawn from the few high-quality studies on NFH [65, 79, 83].

## Discussion

### Neurofilament light

The heterogeneity in reported data comparing NFL between patients with PMS and RRMS appears to be explained by associations with other covariates. Studies reporting higher NFL in RRMS compared to PMS often included a large proportion of RRMS patients during relapses, and in studies reporting higher NFL in PMS compared to RR, the PMS patients were older and a smaller proportion on DMT [4, 41]. The loss of significance between PMS and RRMS when either patients during relapse are excluded, or when multivariate analyses are undertaken including age, EDSS, recent relapses and DMT treatment status as covariates supports this [4, 5, 41].

The most consistent finding in the literature is the association between NFL and inflammatory disease activity in PMS. This replicates findings previously reported in the RRMS population. Whilst studies have also reported associations with cross-sectional clinical measures of disability, these results are less consistent. Associations with longitudinal disability progression are evident in larger cohorts, and are consistently demonstrated with MRI biomarkers of disability progression, such as brain and spinal cord atrophy.

The association of NFL with signs of active inflammation in PMS is supported by data on the ability of

immunosuppressive DMTs to suppress NFL. Second line DMTs have consistently shown a treatment effect on NFL in PMS open-label studies. Whilst open-label studies are susceptible to bias and regression to the mean, such data have now been replicated in randomised controlled trials. Such findings, which have previously been demonstrated for RRMS, suggest that serial bNFL monitoring may be useful in the clinical monitoring of PMS as well as RRMS. As pwPMS tend to be older than pwRRMS, however, there is likely to be reduced signal-to-noise over the background increases in bNFL seen with aging [86], and vigilance will be necessary to exclude alternative sources of raised bNFL that are more prevalent in older PMS patients, such as peripheral neuropathy.

Studies which failed to show a treatment effect upon NFL included either unestablished treatments (mesenchymal stem cells, monthly methylprednisolone, intrathecal rituximab or methotrexate), small studies of first line DMTs (dimethyl fumarate,  $n = 16$ ), or treatments with a purportedly neuroprotective, rather than immunosuppressive, mechanism of action. This latter group, based upon data from the phase 2 RCT of ibudilast and an open-label study of high-dose biotin, again supports the notion of NFL primarily being a marker of neuroinflammation, rather than neurodegeneration, in multiple sclerosis. This is further supported by the results of an RCT using oxcarbazepine, another purportedly neuroprotective treatment, as an add-on therapy in RRMS. Oxcarbazepine did not reduce the primary outcome of CSF NFL, but did slow the rate of disability progression on EDSS [87]. This further questions the utility of NFL as a marker of neuroprotection in multiple sclerosis.

Alternative explanations for the lack of treatment effect on NFL seen with purportedly neuroprotective treatments include the possibility that, compared to immunosuppressive treatments, they are not efficacious enough to demonstrate reductions in NFL, or that their efficacy involves mechanism that do not prevent NFL release. Indeed, in the follow-up phase 3 study, high-dose biotin did not meet its primary or secondary outcomes [88], and the efficacy of ibudilast has yet to be confirmed in a phase 3 trial. The association of NFL with imaging measures of neurodegeneration in non-inflammatory neurodegenerative dementias [89] and the normalised CSF NFL levels seen in response to treatment in spinal muscular atrophy [90] supports the utility of NFL as a biomarker of non-inflammatory neurodegeneration in other neurological conditions. More longitudinal data on NFL from trials of efficacious neuroprotective treatments are, therefore, required before firm conclusions can be reached. There is insufficient evidence at present to support the use of neurofilaments as primary outcome measures in phase 2 trials of *neuroprotective* therapies in progressive multiple sclerosis. Such trials are, therefore, likely to retain primary outcomes based upon measures of brain atrophy.

The association of NFL with inflammatory disease activity and future brain atrophy, however, means NFL may help to identify patients with progressive multiple sclerosis who would benefit from combination therapies including both immunosuppressive and neuroprotective treatment strategies, or to assist in selecting patients for clinical trials who are likely to experience future accelerated brain atrophy, improving trial power.

### Neurofilament heavy

Less data were available on NFH compared to NFL. Multiple studies have reported associations with various measures of current and future disability, as well as MRI markers of future disease progression, but multiple negative results are also reported. Focusing on EDSS, four studies report cross-sectional or longitudinal association; whilst, three found no such associations. Due to heterogeneity in the literature, these findings, therefore, require further confirmation. Given the negative results from studies assessing the treatment effect of reportedly neuroprotective therapies on NFL, the per-protocol analysis finding of reduced bNFH in patients compliant with lamotrigine treatment is of interest. Lamotrigine is not immunosuppressive, and was investigated as a potential neuroprotective therapy. These data, however, must be treated with caution, as the lamotrigine compliant population consisted of only 50% of the intention to treat group [83]. Similar findings were found in a randomised controlled trial of phenytoin in optic neuritis, with a significant reduction in bNFH at 3 months in the phenytoin-treated group compared to controls [91]. The potential of NFH as a marker of neuroprotective treatment response, therefore, warrants further study. Caution is required with bNFH, however, as two studies have failed to show an association between cNFH and bNFH in PMS [80, 84]. Further research using current assay protocols is, therefore, required to confirm an association between bNFH, cNFH and other biomarkers of PMS pathology.

### Limitations

Limitations of this study include incomplete data availability and heterogeneity in the data assessed (for example, CSF and blood neurofilaments, different assays used for neurofilament quantification). A meta-analysis was, therefore, not undertaken, restricting the summary to a qualitative assessment of the literature.

### Conclusions

NFL has shown consistent utility as a biomarker of active neuroinflammation, future brain atrophy and immunosuppressive treatment response in PMS at a *group* level, and shows promising results as a disease intensity marker in non-inflammatory neurodegenerative diseases. Its performance as a biomarker of neurodegenerative pathology or neuroprotective treatment response in PMS is, however, uncertain and requires further research. The literature on NFH in PMS is smaller and less consistent, and whilst one study has suggested its utility as a potential biomarker of neuroprotection, this requires further confirmation.

### Availability of data and material (data transparency)

Online supplementary material included.

**Author contributions** TW and JC contributed to study conception. TW performed the literature review and first draft. All authors contributed to revisions of the manuscript, and approved the final draft.

**Funding** No specific funding was obtained for this article. TW is funded by a fellowship through the MS-STAT2 clinical trial.

### Compliance with ethical standards

**Conflicts of interest** HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Leonard Wolfson Experimental Neurology Centre, and the UK Dementia Research Institute at UCL. In the last 3 years, JC has received support from the National Institute for Health Research (NIHR) EME Programme and Health Technology Assessment Programme (NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. No funders had any role in this article.

**Ethics approval** The manuscript does not contain primary clinical studies or patient data.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.



## References

- Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis. *Neurology* 83:278–286. <https://doi.org/10.1212/WNL.0000000000000560>
- Rissanen DM, Kan CW, Campbell TG et al (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. *Nat Biotechnol* 28:595–599. <https://doi.org/10.1038/nbt.1641.Single-Molecule>
- Novakova L, Zetterberg H, Sundstrom P et al (2017) Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. *Neurology* 89:2230–2237. <https://doi.org/10.1212/WNL.0000000000004683>
- Disanto G, Barro C, Benkert P et al (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. *Ann Neurol* 81:857–870. <https://doi.org/10.1002/ana.24954>
- Barro C, Benkert P, Disanto G et al (2018) Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. *Brain* 141:2382–2391. <https://doi.org/10.1093/brain/awy154>
- Sormani MP, Haering DA, Kropshofer H et al (2019) Blood neurofilament light as a potential endpoint in phase 2 studies in MS. *Ann Clin Transl Neurol*. <https://doi.org/10.1002/acn3.795>
- Leppert D, Kuhle J (2019) Blood neurofilament light chain at the doorstep of clinical application. *Neurol Neuroimmunol NeuroInflammation*. <https://doi.org/10.1212/NXI.0000000000000599>
- Mahajan BKR, Rae-grant A (2018) New American Academy of Neurology disease-modifying treatment guidelines: impact on clinical practice. *Pract Neurol* July/August:22–28
- Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (reprinted from *Annals of Internal Medicine*). *Ann Intern Med* 89:873–880. <https://doi.org/10.1371/journal.pmed.1000097>
- Ferraro D, Guicciardi C, De Biasi S et al (2019) Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients. *Acta Neurol Scand*. <https://doi.org/10.1111/ane.13152>
- Tavazzi E, Bergsland N, Kuhle J et al (2019) A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. *J Neurol*. <https://doi.org/10.1007/s00415-019-09643-z>
- Semra YK, Seidi OA, Sharief MK (2002) Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. *J Neuroimmunol* 122:132–139. [https://doi.org/10.1016/S0165-5728\(01\)00455-6](https://doi.org/10.1016/S0165-5728(01)00455-6)
- Madeddu R, Farace C, Tolu P et al (2013) Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis. *Neurol Sci* 34:181–186. <https://doi.org/10.1007/s10072-012-0974-4>
- Vecchio D, Crespi I, Clemente N et al (2018) CSF biomarkers of neurodegeneration in early multiple sclerosis course. *Mult Scler J* 24:885. <https://doi.org/10.1177/1352458518798592>
- Vecchio D, Clemente N, Comi C et al (2017) CSF kappa free light chains and neurofilaments in multiple sclerosis work up: a pivotal study. *Eur J Neurol* 24:493. <https://doi.org/10.1111/ene.13368>
- Saraste M (2019) Microstructural white matter tract damage measured using DTI-MRI associates with increased serum NFL levels. *Mult Scler J* 25:276–276
- Ferraro D, Guicciardi C, De Biasi S et al (2018) Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients. *Mult Scler J* 24:880. <https://doi.org/10.1177/1352458518798592>
- Högel H, Rissanen E, Barro C et al (2018) Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. *Mult Scler J*. <https://doi.org/10.1177/1352458518819380>
- Hogel H, Rissanen E, Barro C et al (2018) Serum GFAP associates with neurofilament light and disease severity in late multiple sclerosis. *Mult Scler J* 24:658–659. <https://doi.org/10.1177/1352458518798591>
- Zivadnov R, Ramanathan M, Barro C et al (2018) Serum neurofilament light chain levels and cortical pathology in multiple sclerosis: 5-year longitudinal study. *Mult Scler J* 24:997–998. <https://doi.org/10.1177/1352458518799980>
- Khademi M, Dring AM, Gilthorpe JD et al (2013) Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0063172>
- Mañé-Martínez MA, Olsson B, Bau L et al (2016) Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. *J Neuroimmunol* 299:112–117. <https://doi.org/10.1016/j.jneuroim.2016.08.004>
- Novakova L, Axelsson M, Malmström C et al (2018) Searching for neurodegeneration in multiple sclerosis at clinical onset: diagnostic value of biomarkers. *PLoS ONE* 13:1–14. <https://doi.org/10.1371/journal.pone.0194828>
- Iwanowski P, Losy J et al (2016) Neurofilament light, anti-ganglioside M3 antibody and interleukin 18 in relapsing-remitting and primary progressive multiple sclerosis. *Mult Scler J* 22:879. <https://doi.org/10.1177/1352458516664293>
- Malmström C, Haghighi S, Rosengren L et al (2003) Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. *Neurology* 61:1720–1725. <https://doi.org/10.1212/01.WNL.0000098880.19793.B6>
- Teunissen CE, Iacobaeus E, Khademi M et al (2009) Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. *Neurology* 72:1322–1329. <https://doi.org/10.1212/WNL.0b013e3181a0fe3f>
- Baldassari LE, Pope SM, Imrey PB et al (2019) Serum neurofilament light chain in a phase 1/2 trial of autologous mesenchymal stem cell transplantation in multiple sclerosis. *Mult Scler J* 25:30. <https://doi.org/10.1177/1352458519843084>
- Amit B-O (2019) Blood neurofilament light levels are lowered to a healthy donor range in patients with RMS and PPMS following ocrelizumab treatment. *Mult Scler J* 25:52–52
- Burman J, Zetterberg H, Fransson M et al (2014) Assessing tissue damage in multiple sclerosis: a biomarker approach. *Acta Neurol Scand* 130:81–89. <https://doi.org/10.1111/ane.12239>
- Pawlitzi M, Sweeney-Reed CM, Bittner D et al (2018) CSF-progranulin and neurofilament light chain levels in patients with radiologically isolated syndrome-sign of inflammation. *Front Neurol* 9:1075. <https://doi.org/10.3389/fneur.2018.01075>
- Avsar T, Korkmaz D, Tütüncü M et al (2012) Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. *Mult Scler J* 18:1081–1091. <https://doi.org/10.1177/1352458511433303>
- Stilund M, Gjelstrup MC, Petersen T et al (2015) Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. *PLoS ONE* 10:1–22. <https://doi.org/10.1371/journal.pone.0119681>
- Gaetani L, Kina H, Paolo E et al (2017) Neuroinflammation and neuroaxonal damage in multiple sclerosis: a cross-sectional cerebrospinal fluid-based proteomic study. *Mult Scler J* 23:295–296. <https://doi.org/10.1177/1352458517731404>
- Novakova L, Axelsson M, Malmstrom C, Zetterberg H (2017) Accessing early neurodegeneration in multiple sclerosis:

- biomarkers for diagnostics and phenotypic characterization. *Mult Scler J* 23:579. <https://doi.org/10.1177/1352458517731406>
35. Abdelhak A, Hottenrott T, Morenas-Rodriguez E et al (2018) Cerebrospinal fluid markers indicate glial activation and neuroaxonal damage in patients with primary progressive multiple sclerosis. *Mult Scler J* 24:666. <https://doi.org/10.1177/1352458518798591>
  36. Chatterjee M, Koel-Simmelink MJ, Verberk IM et al (2018) Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis. *Mult Scler J Exp Transl Clin* 4:2055217318819535. <https://doi.org/10.1177/2055217318819535>
  37. Abdelhak A, Huss A, Kassubek J et al (2018) Serum GFAP as a biomarker for disease severity in multiple sclerosis. *Sci Rep*. <https://doi.org/10.1038/s41598-018-33158-8>
  38. Kuhle J, Jakimovski D, Barro C et al (2018) Serum neurofilament light chain levels and cross-sectional and longitudinal deep gray matter changes: 5-year longitudinal MRI study. *Mult Scler J* 24:989. <https://doi.org/10.1177/1352458518799980>
  39. Aeinehband S, Lindblom RPF, Nimer FA et al (2015) Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0122048>
  40. Piehl F, Kockum I, Khademi M et al (2018) Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. *Mult Scler J* 24:1046–1054. <https://doi.org/10.1177/1352458517715132>
  41. Martin S-J, McGlasson S, Hunt D, Overell J (2019) Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies. *J Neurol Neurosurg Psychiatry* 90:1059–1067. <https://doi.org/10.1136/jnnp-2018-319190>
  42. Kuhle J, Kropshofer H, Haring DA et al (2018) Neurofilament light levels in the blood of patients with secondary progressive MS are higher than in primary progressive MS and may predict brain atrophy in both MS subtypes. *Mult Scler J* 24:111. <https://doi.org/10.1177/1352458518798579>
  43. Axelsson M, Malmeström C, Gunnarsson M et al (2014) Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. *Mult Scler J* 20:43–50. <https://doi.org/10.1177/1352458513490544>
  44. Sellebjerg F, Börnsen L, Ammitzbøll C et al (2017) Defining active progressive multiple sclerosis. *Mult Scler* 23:1727–1735. <https://doi.org/10.1177/1352458517726592>
  45. Gil-Perotin S, Castillo-Villalba J, Cubas-Núñez L et al (2019) Combined cerebrospinal fluid neurofilament light chain protein and chitinase-3 like-1 levels in defining disease course and prognosis in multiple sclerosis. *Front Neurol*. <https://doi.org/10.3389/fneur.2019.01008>
  46. Bar-Or A (2019) Pretreatment cerebrospinal fluid (CSF) and serum neurofilament light (NfL) levels in patients with PPMS in the OBOE study are correlated and are higher in patients with PPMS with T1 Gd+ brain lesions. *Mult Scler J* 25:494–495
  47. Kapoor R, Sellebjerg F, Hartung H-P et al (2018) Natalizumab reduced serum levels of neurofilament light chain in secondary progressive multiple sclerosis patients from the phase 3 ASCEND study. *Mult Scler J* 24:988. <https://doi.org/10.1177/1352458518799980>
  48. Fox R, Karafa M, König V et al (2019) Effect of Ibudilast on neurofilament-light chain in progressive MS: analysis from a phase II trial (P3.2-033). *Neurology* 92(15 Supplement)
  49. Damasceno A, Carneiro RP, Boldrini VO et al (2018) Predictors of CSF neurofilament levels are different in relapsing and progressive MS. *Mult Scler J* 24:118. <https://doi.org/10.1177/1352458517750968>
  50. Pignolet B, Ammoscato F, Ciron J et al (2019) NfL pattern in progressive multiple sclerosis cohort under MD1003 treatment. *Neurology* 92(15 Supplement)
  51. Kalatha T, Arnaoutoglou M, Koukoulidis T et al (2019) Does cognitive dysfunction correlate with neurofilament light polypeptide levels in the CSF of patients with multiple sclerosis? *J Int Med Res* 47:2187–2198. <https://doi.org/10.1177/0300060519840550>
  52. Eikelenboom MJ, Petzold A, Lazeron RHC et al (2003) Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. *Neurology* 60:219–223. <https://doi.org/10.1212/01.WNL.0000041496.58127.E3>
  53. Kuhle J, Plattner K, Bestwick JP et al (2013) A comparative study of CSF neurofilament light and heavy chain protein in MS. *Mult Scler J* 19:1597–1603. <https://doi.org/10.1177/1352458513482374>
  54. Trentini A, Comabella M, Tintoré M et al (2014) N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. *J Neurol* 261:2338–2343. <https://doi.org/10.1007/s00415-014-7507-4>
  55. Perez-Mirallas F, Prefasi D, Garcia-Merino A et al (2018) Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis. *Mult Scler J* 24:188. <https://doi.org/10.1177/1352458518798582>
  56. Pawlitzki M, Schreiber S, Bittner D et al (2018) CSF neurofilament light chain levels in primary progressive MS: signs of axonal neurodegeneration. *Front Neurol* 9:1–7. <https://doi.org/10.3389/fneur.2018.01037>
  57. Damasceno A, Dias-Carneiro RPC, Moraes AS et al (2019) Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS. *Mult Scler Relat Disord* 30:149–153. <https://doi.org/10.1016/j.msard.2019.02.004>
  58. Abdelhak A, Hottenrott T, Morenas-Rodriguez E et al (2019) Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker? *Front Neurol*. <https://doi.org/10.3389/fneur.2019.00280>
  59. Hardmeier M, Kuhle J, Schlaeger R et al (2017) Biomarker for progressive multiple sclerosis: cross-sectional relationship between disability, multimodal evoked potentials and serum neurofilament light chain in a multicenter study. *Mult Scler J* 23:585–586. <https://doi.org/10.1177/1352458517731406>
  60. Romme Christensen J, Ratzner R, Bornsen L et al (2014) Natalizumab in progressive MS. *Neurology* 82:1499–1507. <https://doi.org/10.1212/WNL.0000000000000361>
  61. Maggi P, Kuhle J, Weigel M et al (2019) Paramagnetic phase rims and serum neurofilaments in relapsing-remitting and progressive multiple sclerosis patients: a combined laboratory-imaging marker of chronic inflammation. *Mult Scler J* 25:51–52
  62. Romme Christensen J, Komori M, von Essen MR et al (2019) CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage. *Mult Scler J* 25:937–946. <https://doi.org/10.1177/1352458518774880>
  63. Hagemeyer J, Tavazzi E, Ramanathan M et al (2019) The association between serum neurofilament light chain and OCT measures in multiple sclerosis. *Neurology* 92(15 Supplement)
  64. Salzer J, Svenningsson A, Sundström P (2010) Neurofilament light as a prognostic marker in multiple sclerosis. *Mult Scler* 16:287–292. <https://doi.org/10.1177/1352458509359725>
  65. Ammoscato F, Sharrack B (2019) CSF neurofilament heavy chain release (NfH) is important in secondary progressive MS (SPMS)—results from the MS-SMART trial. *Mult Scler J* 25:502–503

66. Yildiz O, Mao Z, Adams A et al (2018) Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. *Mult Scler Relat Disord* 24:20–27. <https://doi.org/10.1016/j.msard.2018.05.010>
67. Ratzler R, Christensen JR, Börnsen L et al (2014) Treatment with cyclic oral methylprednisolone in progressive multiple sclerosis—results of an open-label phase 2A proof-of-concept study. *Mult Scler* 20:44. <https://doi.org/10.1177/1352458514546076>
68. Komori M, Lin YC, Cortese I et al (2016) Intrathecal rituximab in progressive MS stopped for insufficient inhibition of CNS inflammation: a randomized, doubleblind, placebo-controlled study. *Mult Scler* 22:65. <https://doi.org/10.1177/13524585166631279>
69. Harris VK, Tuddenham J, Zanker S, Vyshkina T (2017) Intrathecal autologous cell therapy is associated with changes in cerebrospinal fluid biomarkers in patients with progressive multiple sclerosis. *Mult Scler J* 23:579. <https://doi.org/10.1177/135245851731406>
70. Edwards KR, Siuta J, Button J et al (2017) Neuronal and glial CSF biomarkers in patients with secondary progressive multiple sclerosis treated with dimethyl fumarate. *Mult Scler J* 23:838–839. <https://doi.org/10.1177/1352458517731285>
71. Zanker S, Harris V (2017) CSF biomarkers of disease progression in patients with multiple sclerosis. *Neurology* 88(16 Supplement)
72. Bergman J, Burman J, Gilthorpe JD et al (2018) Intrathecal treatment trial of rituximab in progressive ms an open-label phase 1b study. *Neurology* 91:E1893–E1901. <https://doi.org/10.1212/WNL.0000000000006500>
73. Kuhle J, Kropshofer H, Barro C et al (2018) Siponimod reduces neurofilament light chain blood levels in secondary progressive multiple sclerosis patients. *Advanstar Communications*, vol. 90. *Neurology*, pp S8.006 (15 Supplement)
74. Blum A et al (2010) The relation of quantitative MRI measures, CSF markers and disability in multiple sclerosis. *Mult Scler* 16:S190. <https://doi.org/10.1177/1352458510383204>
75. Uzunkopru C, Yuceyar N, Taskiran D et al (2014) Correlation of neurofilaments and nitrotyrosine with retinal nerve fiber layer thickness and disability in different phases of multiple sclerosis. *Mult Scler* 20:184. <https://doi.org/10.1177/1352458514546077>
76. Kaymakzade B, Kurne AT, Tumani H et al (2014) Evaluation of neurofilament heavy chain levels in progressive multiple sclerosis patients: preliminary results. *J Neurol* 261:S453. <https://doi.org/10.1007/s00415-014-7337-4>
77. Gresle M, Liu Y, Dagley LF et al (2014) Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients. *J Neurol Neurosurg Psychiatry* 85:1209–1213. <https://doi.org/10.1136/jnnp-2013-306789>
78. Petzold A, Eikelenboom MJ, Keir G et al (2005) Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. *J Neurol Neurosurg Psychiatry* 76:206–211. <https://doi.org/10.1136/jnnp.2004.043315>
79. Kuhle J, Leppert D, Petzold A et al (2011) Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. *Neurology* 76:1206–1213. <https://doi.org/10.1212/WNL.0b013e31821432ff>
80. Vorobyeva A, Fominykh V, Zakharova M (2013) Biochemical markers of neurodegeneration in multiple sclerosis. *Mult Scler* 19:369. <https://doi.org/10.1177/1352458513502429>
81. Altintas A, Akkas SY, Lehmensiek V (2014) CSF proteomic profile in primary progressive multiple sclerosis. *J Neurol* 261:S443. <https://doi.org/10.1007/s00415-014-7337-4>
82. Rommer PS, Kamin F, Petzold A et al (2014) Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients. *Mol Diagn Ther* 18:631–637. <https://doi.org/10.1007/s40291-014-0114-3>
83. Gnanapavan S, Grant D, Morant S et al (2013) Biomarker report from the phase II lamotrigine trial in secondary progressive MS—neurofilament as a surrogate of disease progression. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0070019>
84. Eikelenboom MJ, Uitdehaag BMJ, Petzold A (2011) Blood and CSF biomarker dynamics in multiple sclerosis: implications for data interpretation. *Mult Scler Int* 2011:823176. <https://doi.org/10.1155/2011/823176>
85. Petzold A, Mondria T, Kuhle J et al (2010) Evidence for acute neurotoxicity after chemotherapy. *Ann Neurol* 68:806–815. <https://doi.org/10.1002/ana.22169>
86. Khalil M, Pirpamer L, Hofer E et al (2020) Serum neurofilament light levels in normal aging and their association with morphologic brain changes. *Nat Commun* 11:1–9. <https://doi.org/10.1038/s41467-020-14612-6>
87. Marta M, Bianchi L, Lieberman D et al (2019) Oxcarbazepine as a neuroprotective agent in MS: a phase IIa trial (PROXIMUS). *Mult Scler J* 25:91
88. MedDay\_Pharmaceuticals (2020) MedDay reports top-line data from phase III trial “SPI2” for treatment of progressive forms of multiple sclerosis. <http://www.medday-pharma.com>. Accessed 10 Mar 2020
89. Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. *Nat Rev Neurol* 14:577–589. <https://doi.org/10.1038/s41582-018-0058-z>
90. Olsson B, Alberg L, Cullen NC et al (2019) NFL is a marker of treatment response in children with SMA treated with nusinersen. *J Neurol* 266:2129–2136. <https://doi.org/10.1007/s00415-019-09389-8>
91. Tourbah S, Grant D, Raftopoulos R, Hickman S, Altmann D, Barro C, Blennow K, Zetterberg H, Kapoor R, Giovannoni GJK (2016) Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. In: *ECTRIMS*, vol 146047, p 1619